Uniqure (NASDAQ:QURE)‘s stock had its “buy” rating restated by analysts at Janney Montgomery Scott in a note issued to investors on Tuesday, Stock Target Advisor reports.
Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 target price (up from $60.00) on shares of Uniqure in a report on Monday, February 11th. Chardan Capital boosted their price objective on shares of Uniqure from $70.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Cantor Fitzgerald reissued a “buy” rating and issued a $81.00 price objective on shares of Uniqure in a research note on Thursday, March 7th. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Monday, February 25th. Finally, SunTrust Banks boosted their price objective on shares of Uniqure to $76.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Uniqure has an average rating of “Buy” and a consensus target price of $75.82.
Shares of Uniqure stock opened at $69.91 on Tuesday. The firm has a market capitalization of $2.64 billion, a PE ratio of -29.88 and a beta of 0.95. Uniqure has a 12 month low of $21.98 and a 12 month high of $78.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51.
Uniqure (NASDAQ:QURE) last announced its earnings results on Monday, April 29th. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.03). The business had revenue of $1.14 million during the quarter, compared to analyst estimates of $2.00 million. Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%. As a group, equities research analysts expect that Uniqure will post -3.01 EPS for the current fiscal year.
In other Uniqure news, CEO Matthew C. Kapusta sold 8,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $58.38, for a total value of $467,040.00. Following the transaction, the chief executive officer now directly owns 421,730 shares of the company’s stock, valued at approximately $24,620,597.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Philip Astley-Sparke sold 6,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $59.84, for a total transaction of $359,040.00. Following the completion of the transaction, the director now directly owns 19,272 shares in the company, valued at $1,153,236.48. The disclosure for this sale can be found here. Insiders sold a total of 21,546 shares of company stock worth $1,296,260 over the last three months. 2.91% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of QURE. Opaleye Management Inc. purchased a new stake in shares of Uniqure during the 1st quarter worth $12,228,000. Vivo Capital LLC purchased a new stake in shares of Uniqure in the 1st quarter worth about $10,757,000. 683 Capital Management LLC boosted its position in shares of Uniqure by 10.3% in the 4th quarter. 683 Capital Management LLC now owns 1,085,000 shares of the biotechnology company’s stock worth $31,270,000 after buying an additional 100,900 shares in the last quarter. OppenheimerFunds Inc. boosted its position in shares of Uniqure by 5.2% in the 1st quarter. OppenheimerFunds Inc. now owns 1,817,534 shares of the biotechnology company’s stock worth $108,416,000 after buying an additional 90,391 shares in the last quarter. Finally, Macquarie Group Ltd. boosted its position in shares of Uniqure by 13.9% in the 1st quarter. Macquarie Group Ltd. now owns 680,000 shares of the biotechnology company’s stock worth $40,562,000 after buying an additional 83,000 shares in the last quarter. Institutional investors own 60.12% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Featured Article: Cost of equity and a company’s balance sheet
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.